Notably, hydroxylated chalcone inhibits Aβ aggregation and ferroptosis by exerting a pharmacological effect on factors for iron-induced death (including GPX4 or Xc– inhibition); therefore, it could be a candidate treatment for AD (Cong et al., 2019). Here, GPX4 is linked to Alzheimer disease.